In a rodent diabetic nephropathy model, treatment with the mitochondria‐targeted peptide SS31 reduced OMA1 levels, restored mitochondrial function, and mitigated podocyte injury [52]. This evidence concerns the gene OMA1 and diabetic kidney disease.